The announcement of an £11.5m repeat contract with an existing top-tier global pharma client underlines hVIVO’s value-proposition and the capabilities of its RSV Human Challenge Study Model. The reiterated FY24 guidance for £62m revenue comes with EBITDA margins anticipated at the upper end of expectations. We believe the recent share price fall unduly discounts hVIVO’s long-term potential given our 42p target price, and we look to further news flow and the company’s FY24 trading update, expecte ....
